May 7, 2019 / 11:11 AM / 2 months ago

Allergan reports bigger first-quarter loss on $2.5 bln charge

May 7 (Reuters) - Allergan Plc posted a bigger first-quarter loss on Tuesday as it recorded a charge of about $2.5 billion related to the clinical failure of its depression treatment candidate rapastinel.

Net loss widened to $2.41 billion, or $7.25 per share, in the first quarter ended March 31, from $332.5 million or 99 cents a share, a year earlier.

Revenue fell 2 percent to $3.59 billion. (Reporting by Manojna Maddipatla and Manas Mishra in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below